On the 8th, Anges <4563> announced its consolidated financial results for the third quarter of the fiscal year ending December 2024 (January to September 24). Revenue increased by 359.4% to 0.471 billion yen compared to the same period last year, operating loss was 7.042 billion yen (compared to a loss of 9.207 billion yen in the same period last year), ordinary loss was 7.05 billion yen (compared to a loss of 4.72 billion yen), and net quarterly loss attributable to the parent company's shareholders amounted to 7.156 billion yen (compared to a loss of 4.798 billion yen).
Business revenue for the cumulative period of the third quarter has shown a significant increase compared to the same period last year. Within the company group, sales of the progeria treatment drug 'Zokinvi' began on May 27, 2024, generating sales of 0.185 billion yen. Additionally, the HGF gene therapy product Collategene obtained approval for conditional and time-limited manufacturing and sales, previously sold by Tanabe Mitsubishi Pharma since September 2019. Although an application for manufacturing and sales approval for the removal of conditions was submitted in May 2023, it was temporarily withdrawn in June 2024, leading to the expiration of the approval deadline and termination of sales. As a result, product sales decreased by 0.003 billion yen to 0.011 billion yen compared to the same period last year. On the other hand, at Anges Clinical Research Laboratory, in addition to the expanded newborn screening conducted by the Association for Promoting Medical Care and Research for Rare Diseases, contracts to expand newborn screening have commenced from the Gunma Prefectural Health Foundation and the Saitama Children's Medical Center. With the steady increase in the number of contracts for expanding newborn screening compared to the same period last year, fee income of 0.199 billion yen (a 0.125 billion yen increase compared to the same period last year) was recorded. Furthermore, the consolidated subsidiary EmendoBio Inc. signed a license agreement with Anocca AB from Sweden for the non-exclusive use rights of OMNI nucleases developed for genome editing, recording a research and development revenue from the contract's upfront payment of 0.075 billion yen.
For the full fiscal year ending December 2024, we maintain the upward-revised consolidated performance forecast announced on March 14, which is 0.6 billion yen in revenue (292.2% increase from the previous year), 8.45 billion yen in operating loss, 8.45 billion yen in ordinary loss, and 8.65 billion yen in net loss attributable to shareholders of the parent company.
